Fri, September 17, 2021
Thu, September 16, 2021
Wed, September 15, 2021

Vikram Purohit Maintained (TBPH) at Sell with Decreased Target to $10 on, Sep 16th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-10-on-sep-16th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Vikram Purohit of Morgan Stanley, Maintained "Theravance Biopharma, Inc." (TBPH) at Sell with Decreased Target from $14 to $10 on, Sep 16th, 2021.

Vikram has made no other calls on TBPH in the last 4 months.



There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021


This is the rating of the analyst that currently disagrees with Vikram


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021